Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 2/2013

01-06-2013 | Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Non-Size-Based Response Criteria to Preoperative Chemotherapy in Patients With Colorectal Liver Metastases: The Morphologic Response Criteria

Authors: Junichi Shindoh, Yun Shin Chun, Evelyne M. Loyer, Jean-Nicolas Vauthey

Published in: Current Colorectal Cancer Reports | Issue 2/2013

Login to get access

Abstract

Since the introduction of biological agents, accumulating results have suggested that conventional size-based RECIST criteria do not enable accurate assessment of response to therapy, and that non-size-based changes in tumor morphology can be a surrogate marker for assessment of chemotherapeutic effect. The morphological response criteria are recently introduced, non-size-based criteria for patients undergoing chemotherapy for colorectal liver metastases (CLM). These novel criteria predict pathologic response and long-term survival of patients treated with preoperative chemotherapy, with or without bevacizumab, irrespective of their RECIST response. They have been validated in patients with resectable and unresectable CLM. These criteria are difficult to apply for small metastases and can be used as an adjunct to RECIST in assessment of response to preoperative chemotherapy.
Literature
1.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef
2.
Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245–51.PubMedCrossRef
3.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef
4.
Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357–65.PubMed
5.
Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619–28.PubMedCrossRef
6.
Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012–20.PubMedCrossRef
7.
Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010;21:936–41.PubMedCrossRef
8.
Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.PubMedCrossRef
9.
Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010;194:157–65.PubMedCrossRef
10.
Smith AD, Shah SN, Rini BI, et al. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010;194:1470–8.PubMedCrossRef
11.
•• Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338–44. This paper and Ref. [18] first indicated the clinical relevance and predictive value of morphologic response criteria for patients undergoing chemotherapy for colorectal liver metastases. These studies showed that optimal morphologic response is associated with better survival, irrespective of the chemotherapy regimens or surgical treatment used.PubMedCrossRef
12.
De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508–15.PubMedCrossRef
13.
• Suzuki C, Blomqvist L, Sundin A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012;23:948–54. This paper reported the limitation of the current version of RECIST in predicting patient outcomes after modern chemotherapy and also indicated the possibility of improving the diagnostic value of RECIST by modifying current cut-off values.PubMedCrossRef
14.
Glimelius B, Sorbye H, Balteskard L, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol. 2008;19:909–14.PubMedCrossRef
15.
Blazer 3rd DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344–51.PubMedCrossRef
16.
Maru DM, Kopetz S, Boonsirikamchai P, et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010;34:1287–94.PubMedCrossRef
17.
Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.PubMedCrossRef
18.
•• Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30:4566–72. This paper and Ref. [11] first indicated the clinical relevance and predictive value of morphologic response criteria for patients undergoing chemotherapy for colorectal liver metastases. These studies showed that optimal morphologic response is associated with better survival, irrespective of the chemotherapy regimens or surgical treatment used.
Metadata
Title
Non-Size-Based Response Criteria to Preoperative Chemotherapy in Patients With Colorectal Liver Metastases: The Morphologic Response Criteria
Authors
Junichi Shindoh
Yun Shin Chun
Evelyne M. Loyer
Jean-Nicolas Vauthey
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Colorectal Cancer Reports / Issue 2/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0164-7

Other articles of this Issue 2/2013

Current Colorectal Cancer Reports 2/2013 Go to the issue

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Safety of Simultaneous Bowel and Liver Resections for Colon and Rectal Cancer

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Management of the Hepatic Lymph Nodes During Resection of Liver Metastases from Colorectal Cancer: A Systematic Review

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

The ALPPS Approach for the Management of Colorectal Carcinoma Liver Metastases

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Irreversible Electroporation: a Novel Option for Treatment of Hepatic Metastases

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Is There a Role for Neoadjuvant Chemotherapy Without Radiotherapy in Locally Advanced Rectal Cancer?

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

How Could the TNM System Be Best Adapted for Staging Rectal Cancer in the Future?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits